Cyclin E1's role in the immune environment of ovarian cancer and possible new treatments
The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting
This research explores whether targeting a protein called Cyclin E1 can change immune cells around high-grade serous ovarian tumors to help treatments work better for patients whose tumors have high Cyclin E1.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11300178 on NIH RePORTER |
What this research studies
Researchers will study ovarian tumors that have extra copies or high levels of the Cyclin E1 (CCNE1) protein using lab-grown human tumor models and mouse models that carry human immune cells. They will look at how Cyclin E1 affects key immune signals like IRF1 and type I interferons and how it shapes tumor-associated macrophages in the tumor neighborhood. The team will test therapies that could reverse the immune-suppressive effects tied to Cyclin E1 overexpression and see which approaches slow tumor growth in these models. Findings will guide development of treatments aimed at Cyclin E1-amplified, chemotherapy-resistant high-grade serous ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates are people with high-grade serous ovarian cancer whose tumors show CCNE1 (Cyclin E1) amplification or high Cyclin E1 expression, especially those without BRCA-related DNA repair defects.
Not a fit: Patients whose tumors lack Cyclin E1 overexpression or who have BRCA-mutant, homologous-recombination-deficient tumors that already respond to PARP inhibitors are less likely to benefit from these specific Cyclin E1-targeted strategies.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that overcome chemoresistance and improve outcomes for patients with Cyclin E1–high high-grade serous ovarian cancer.
How similar studies have performed: This is a relatively new direction—while PARP inhibitors help BRCA-deficient ovarian cancers, there are currently no established therapies specifically proven for CCNE1-amplified ovarian cancers, making this approach novel.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Ding, Liya — Roswell Park Cancer Institute Corp
- Study coordinator: Ding, Liya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.